Trichostatin A, an inhibitor for histone deacetylase (HDAC), in combination with targeted therapy, has been reported to contribute to the selective ablation of DTCs derived from lung cancer in vivo and in vitro44, 45; however, Trichostatin A could not eliminate melanoma‐derived DTCs after exposure to targeted therapy.153. This evidence concerns the gene HDAC9 and lung cancer.